Biomarkers reveal vital insights that could improve treatment strategies for aggressive prostate cancer, offering hope for ...

Many men with aggressive prostate cancer can experience a high rate of recurrence despite treatment. A new Phase 2 clinical ...

THOUSANDS more men should receive an existing prostate cancer drug on the NHS as research shows it could halve their death ...

A new artificial intelligence (AI) test can identify which men with prostate cancer will benefit most from the life-extending ...

Exosomes transform prostate cancer care with early detection, tailored treatments, and real-time prognosis tracking for ...

As with the drug's 2023 approval in castration-resistant tumors, it's not clear if it works comparably in all homologous ...

Notably, the ARCHES trial had the longest median follow-up among ARPI trials at 61.4 months. During this period, median overall survival was not reached in either treatment arm. At 5 years, 66% (two ...

At the recent American Urological Association annual meeting, data on niraparib (Zejula) in treatment-naive, DNA damage ...

Prostate cancer is the most common cancer affecting American men other than skin cancer and the second leading cause of male ...

New treatment combinations are transforming genitourinary cancer care, improving survival and quality of life while ...

In GC, CBR3-AS1 and PCA3 may be utilized as therapeutic targets and prognostic biomarkers, respectively."BUFFALO, NY- June 5, 2025 – A new research ...